Résultat de la recherche

9 recherche sur le mot-clé 'xylazine'

  Tris disponibles Ajouter le résultat à votre sélection   Affiner la recherche    Générer le flux rss de la recherche    Partager le résultat de cette recherche

Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug-testing and law enforcement

C. S. COPELAND ; K. RICE ; K. L. ROCK ; S. HUDSON ; P. STREETE ; A. J. LAWSON ; L. COUCHMAN ; A. HOLLAND ; S. MORLEY | 2024
Dans Addiction (Vol.119, n°7, July 2024) Article : Périodique

BACKGROUND AND AIMS: Xylazine is a non-opioid sedative which has spread rapidly throughout the US illicit drug supply. This study aimed to describe the spread of xylazine throughout the UK illicit drug supply. METHODS: Xylazine detections in h[...]

Plus d'info

Ajouter à la sélection

Lien externe

Clinical considerations for the management of xylazine overdoses and xylazine-related wounds [Editorial]

K. L. SUE ; K. HAWK | 2024
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique

This editorial reviews literature on xylazine as well as major clinical considerations for treatment and management of suspected xylazine-involved overdoses and xylazine-related wounds. The clinical presentation and management of xylazine overdo[...]

Plus d'info

Ajouter à la sélection

Lien externe

Media framing xylazine as a "zombie drug" is amplifying stigma onto people who use drugs [Commentary]

J. M. BOWLES ; E. C. COPULSKY ; M. K. REED | 2024
Dans International Journal of Drug Policy (Vol.125, March 2024) Article : Périodique

Amid increasing efforts to understand xylazine-associated harms, examining the potentially catastrophic role of stigma resulting from media outlets framing xylazine as the "zombie drug" is imperative. Zombies are cinematically depicted as soulle[...]

Plus d'info

Ajouter à la sélection

Lien externe

Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

D. T. ZHU | 2023
Dans Harm Reduction Journal (Vol.20, 2023) Article : Périodique

INTRODUCTION: Xylazine, an alpha2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates have surged in recent years, fueled by an increasingly toxic and [...]

Plus d'info

Ajouter à la sélection

Lien externe

Widespread distribution of xylazine detected throughout the United States in healthcare patient samples

A. C. HOLT ; D. M. SCHWOPE ; K. LE ; J. P. SCHRECKER ; R. HELTSLEY | 2023
Dans Journal of Addiction Medicine (Vol.17, n°4, July-August 2023) Article : Périodique

OBJECTIVES: Xylazine is a tranquilizer commonly added into the illicit drug supply and a likely contributor to overdoses because it does not respond to naloxone reversal. The objective of this study was to perform a retrospective data analysis o[...]

Plus d'info

Ajouter à la sélection

Lien externe

'Zombie drugs': Dehumanising news frames and public stigma towards people who use drugs

H. R. SUMNALL ; A. HOLLAND ; A. M. ATKINSON ; C. MONTGOMERY ; J. NICHOLLS ; O. M. MAYNARD | 2025
Dans International Journal of Drug Policy (Vol.136, February 2025) Article : Périodique

Background: News media is an important determinant of public understanding of drug policy topics. Recent media reporting around the use of synthetic drugs such as xylazine makes frequent use of non-human metaphors, including reference to the eff[...]

Plus d'info

Ajouter à la sélection

Lien externe

NDTA - National drug threat assessment 2024

US Department of Justice ; Drug Enforcement Administration | 2024
Rapport

The 2024 National Drug Threat Assessment (NDTA) is a comprehensive strategic assessment of illicit drug threats endangering the United States. DEA's goal in publishing the NDTA is to save American lives by raising awareness and understanding of [...]

Plus d'info

Ajouter à la sélection

Lien externe

NDTA - National drug threat assessment 2025

US Department of Justice ; Drug Enforcement Administration | 2025
Rapport

The Drug Enforcement Administration (DEA) presents the 2025 National Drug Threat Assessment (NDTA), a comprehensive report that provides a national-level perspective on the threats posed by deadly illicit drugs and the violent transnational crim[...]

Plus d'info

Ajouter à la sélection

Lien externe

New psychoactive substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory

J. J. MILLER ; M. YAZDANPANAH ; D. A. COLANTONIO ; D. R. BERIAULT ; S. R. DELANEY | 2024
Dans Clinical Biochemistry (Vol.133-134, December 2024) Article : Périodique

The production and use of New Psychoactive Substances (NPS) has skyrocketed over the last decade, causing major challenges for government authorities, public health agencies, and laboratories across the world. NPS are designed to mimic the psych[...]

Plus d'info

Ajouter à la sélection

Lien externe